Brief: Lifecore Biomedical Reports Financial Results For The Fourth Quarter And Transition Period Ended December 31, 2025, And Provides Corporate Update
16/03/2026 12:17
March 16 (Reuters) - Lifecore Biomedical Inc LFCR.O: LIFECORE BIOMEDICAL REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND TRANSITION PERIOD ENDED DECEMBER 31, 2025, AND PROVIDES CORPORATE UPDATE LIFECORE BIOMEDICAL INC - EXPECTS 2026 REVENUE $120-$125 MILLION; ADJUSTED EBITDA $20.5-$25 MILLION LIFECORE BIOMEDICAL INC - Q4 REVENUE $35.7 MILLION LIFECORE BIOMEDICAL INC: Q4 EPS $-0.16 Source text: ID:nGNX90ryKz Further company coverage: LFCR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lifecore Biomedical
See all newsNASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:40 AM
Lifecore Biomedical, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Lifecore Biomedical Reports Financial Results
Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview